Longstanding concern exists regarding the potential for women with breast implants to experience delayed detection of breast cancer. Furthermore, survival among cosmetic breast implant patients who subsequently develop breast cancer is a concern. Since 1976, this institution has monitored cancer incidence in a cohort of 3182 women who underwent cosmetic breast augmentation between 1959 and 1981. The distributions of stage at diagnosis and survival of the 37 women who subsequently developed in situ or invasive breast cancer were compared with the observed population distributions. The distribution of stage at diagnosis for cosmetic breast implant patients who subsequently developed breast cancer was virtually identical to that of all breast cancer patients in Los Angeles County who were of the same age and race, and were diagnosed during the same time period. Furthermore, the 5-year survival rate of the 37 patients did not differ from that which would be expected based on rates established by the U.S. National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program.
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These results suggest that cosmetic breast implant patients are not at increased risk of delayed detection of breast cancer, nor do they suffer a poorer prognosis when breast cancer does occur. Although the number of breast cancer patients in this study is small, the results are highly consistent with the existing epidemiologic evidence related to breast cancer detection and survival among breast implant patients. Although breast implant patients should continue appropriate breast cancer screening behavior, there seems to be no cause for alarm. (Plast. Reconstr. Surg. 105: 535, 2000.) Recent studies have consistently shown that risk of breast cancer is not increased among women with breast implants. [1] [2] [3] [4] [5] [6] [7] Furthermore, although population-based studies show that the diagnosis of breast cancer is not delayed, as indicated by clinical stage at diagnosis, 8 reports of case series are mixed, with both favorable 9 -12 and unfavorable 13, 14 results. It has been speculated that breast cancers may be more aggressive among patients with breast implants than among those without, 15 resulting in a poorer survival rate among implant patients. In a cohort of more than 3000 augmentation mammaplasty patients, we have observed 37 incident breast cancer patients who were diagnosed before 1993. We compared the 5-year and individual year survival intervals of these patients with those derived from population-based figures obtained by the National Cancer Institute's SEER registries, adjusting for breast cancer stage and age at diagnosis.
MATERIALS AND METHODS
Since 1976, we have been monitoring cancer incidence in a cohort of 3182 non-Spanishsurnamed white women in Los Angeles County who had cosmetic breast augmentation during the period 1959 to 1981. 2 The cohort was established by abstracting medical records from the practices of 35 board-certified plastic surgeons. Patients with prophylactic subcutaneous mastectomy or breast carcinoma before implantation were excluded, as were nonresidents of Los Angeles County.
Cancer incidence has been determined by record linkage of the cohort with the Los Angeles County Cancer Surveillance Program, the population-based cancer registry that has cov- Observed cumulative survival rates for the breast cancer patients with prior augmentation mammaplasty were estimated annually through year 5, overall and by stage of disease, by using the product limit method, with 95 percent confidence intervals for the 5-year survival rate estimated by using Greenwood's formula for the standard error. 17 Expected survival rates for these patients were generated by indirectly adjusting for age, year of diagnosis, and stage on the basis of the relative survival rates for white women provided by the National Cancer Institute's SEER Program (Lynn Ries, personal communication). To do this, the SEER rates within each of the specific categories have been weighted by the age-, stage-, and year of diagnosis-specific percentages of the augmentation mammaplasty breast cancer patients.
RESULTS
Of 3182 women in the cohort, 37 were diagnosed with in situ or invasive breast cancer between 1975 and 1992. Among these, 73 percent had received silicone gel filled devices at first implantation (the reminder received saline, double-lumen, or other implant types); 75 percent of the entire cohort received silicone gel implants (Table I ). Six of the 37 patients died from breast cancer; 4 of these had silicone gel filled implants and two had saline filled implants.
The average age at implant of the 37 patients was 38.1 years, and the average age at breast cancer diagnosis was 50.3 years (Table II) . These patients have been followed, on average, for 18.7 years since their implant surgery, with an average of 6.6 of these years occurring after the breast cancer diagnosis. The postdiagnosis follow-up period ranged from 0.2 to 17.3 years, with 19 of 37 patients having more than 5 years of postdiagnosis follow-up.
Five patients (14 percent) were diagnosed with in situ breast cancer, 19 (51 percent) had localized disease, and 13 (35 percent) were diagnosed with regional or distant disease. When compared with the distribution of summary stage at diagnosis for all Los Angeles County non-Spanish-surnamed, white, female breast cancer patients 35 to 74 years old diagnosed during 1976 to 1991, the distribution of stage at diagnosis among the implanted patients was very similar to the expected distribution (Table III) . Of the 37 patients, 24 were diagnosed before the 1988 publication of specialized imaging techniques for the augmented breast. 18 Of the six patients who died, four deaths occurred within 2 years of the breast cancer diagnosis (at 3 months, 4 months, 1.1 years, and 1.8 years, respectively); the other two deaths occurred 7.5 and 9.8 years after diagnosis, respectively. Among the four patients who died within 2 years of their diagnosis, two had distant disease at diagnosis and two had regional disease. The two patients whose deaths (Table  IV) . The expected survival rates are also shown in Table IV . The results indicate that for in situ disease, survival for the augmentation mammaplasty patients is the same as the expected survival, and survival with localized disease is slightly better than the expected survival. For regional and distant disease, survival among patients with implants is slightly lower than expected during the first few years after diagnosis, but the rates nearly converge at 5 years. The small number of patients on which these findings are based is reflected in the wide confidence intervals surrounding the estimated cumulative survival probabilities for these patients. At 5 years, for example, the observed survival rate is 65.8 percent for augmentation mammaplasty patients with regional or distant disease, with the 95 percent confidence interval ranging from 38.2 to 93.4 percent. The expected rate based on SEER data was 67.1 percent. When all patients are combined, the observed survival rate for the augmentation mammaplasty patients is 88.5 percent (95 percent confidence limits 77.8 to 99.1 percent) versus an expected rate 84.1 percent.
DISCUSSION
The estimated proportion of breast tissue that is obscured from mammographic examination by silicone breast implants ranges from 25 to 80 percent. 14 Previous reports, based on case series, have provided conflicting evidence regarding the effect of implants on stage at diagnosis. Among 20 augmented and 733 nonaugmented breast cancer patients, all augmented patients presented with a palpable mass; many of them reported substantial delays in seeking care. 13 Although mammography was performed on 75 percent (15 of 20) of patients, the palpable lesion was not visualized in 33 percent (5 of 15). All lesions were invasive, and 65 percent had lymph node involvement. In a subanalysis, 331 age-matched controls were selected. Although the mean tumor size in the matched cases and controls did not differ, the nonaugmented patients were diagnosed at an earlier stage, with 25 percent having in situ lesions and 26 percent having involved axillary nodes. In a subsequent report, with the number of augmented breast cancer patients increased to 42, a 40 percent false negative rate for mammography was reported. Although the augmented breast cancer patients were similar in terms of tumor size and nodal positivity to nonaugmented breast cancer patients who presented with palpable masses, the augmented patients had a higher percentage of invasive lesions and involved axillary lymph nodes when compared with breast cancers found by screening mammography. 14 Standard two-view mammography apparently had low sensitivity in detecting palpable cancer among augmented patients in a series of 35 augmentation mammaplasty patients with subsequent breast cancer; abnormalities were detected in only 17 of 31 patients by standard compression mammography. 9 However, the authors did report that the stage at diagnosis of these patients was not delayed. The average age at implant was 38 years and at diagnosis was 46 years; 8 percent of the patients had in situ disease, 49 percent had local disease, and 43 percent had regional, or distant, metastatic disease. These ages and stages are similar to those observed among the 37 Los Angeles patients. After a median follow-up period of 3.2 years, two patients had died with an overall actuarial 5-year survival rate of 45.7 percent.
In a series of 25 augmentation mammaplasty patients with breast cancer, mammography was positive for 20 (80 percent). 24 Among these 25 patients, whose average age at diagnosis was 45.3 years, seven women were asymptomatic and referred for screening mammography; only 28 percent of the 25 patients presented with nodal metastases. In another study, records of 33 augmented patients with subsequent breast cancer were compared with 1735 nonaugmented breast cancer patient controls. 11 The augmented patients had significantly fewer positive axillary lymph nodes and significantly more often had tumors smaller than 2 cm. There was no difference in the frequency of in situ disease. A similar retrospective review of 22 cosmetic breast augmentation patients with subsequent breast cancer and 611 breast cancer controls revealed no significant differences in mean tumor size, incidence of preinvasive disease, and axillary lymph node involvement. 12 Poorer results were reported from a series of nine augmentation mammaplasty patients with breast cancer. 22 The mean age at implant was 36 years, and the mean interval between augmentation and development of a palpable mass was 6.4 years. All nine patients detected the breast mass by self-examination, and six delayed seeking medical attention for at least 2 or 3 months. Seven of the patients had mammography as part of the diagnostic evaluation, but only one mass was detected. Five patients had localized disease and four had more extensive disease at diagnosis. After a mean follow-up of 4.75 years, one patient had died with metastatic disease.
Case series are rarely able to represent a population-based experience. In fact, clinics with superior reputations might be expected to suffer the greatest degree of referral bias, i.e., more severe or unusual cases are likely to be referred to the specialty practice. The advantage of population-based studies is the ability to observe cancer incidence, stage at diagnosis, and survival in a well-defined group of women. Forty-one women from Alberta, Canada, who developed breast cancer after cosmetic breast augmentation were compared with all other women in Alberta with breast cancer in the same era. 8 As in the present study, the extent of disease (i.e., stage) at diagnosis did not differ between augmentation patients and the population of breast cancer patients. The tumors that occurred among augmentation patients were actually smaller than the tumors in women without implants. The 5-and 10-year survival rates for women with implants were 83 percent and 73 percent, respectively, in comparison with 74 percent and 62 percent for nonimplanted breast cancer patients.
Thirty-six breast cancer patients reported prior breast augmentation in a large breast cancer case-control study. 7 Nearly 6 percent of these had been diagnosed with in situ tumors; 58 percent had localized tumors, and 36 percent had distant metastasis. This stage distribution is similar to that observed among our 37 patients.
The Los Angeles and Alberta cohorts include only cosmetic augmentation patients. In a study of postmastectomy reconstruction patients, French investigators evaluated 146 patients who received gel-filled silicone implants and compared them with an equal number of postmastectomy control patients without reconstruction, matched for age at diagnosis, year of diagnosis, stage, histologic type, grade, and nodal status. 10 The 10-year survival rate was 90 percent among the implanted patients and 82 percent among the nonimplanted controls. The risks of distant metastasis and death caused by breast cancer were significantly lower in the breast implant group. Risks of local recurrence, second breast cancer, and second primary cancer at sites other than the breast were not significantly different between the two groups.
In Los Angeles, we found that, overall, women with cosmetic breast augmentation have stage presentations similar to those of other breast cancer patients and 5-year survival rates similar to those that would be predicted by National Cancer Institute's SEER survival rates. Clearly, the relatively small number of breast cancer patients in this cohort limits the conclusions that can be drawn at this time. However, taken together with the additional available evidence from other studies, breast implant patients seem to experience no delay in diagnosis and no decrease in survival.
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